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doi:10.1016/j.jmii.2011.01.032Background: To determine whether the susceptibilities and the trends of nonsusceptibility of
imipenem, meropenem, sulbactam, and colistin differed among Acinetobacter baumannii, Aci-
netobacter genomic species 3 (AGS 3), and Acinetobacter genomic species 13TU (AGS 13TU)
over 11 years.
Methods: A total of 1,039 nonduplicate blood isolates of A baumannii complex from bacter-
emic patients between 1997 and 2007 were collected at Taipei Veterans General Hospital
and were identified to the species level using a multiplex polymerase chain reaction method
and sequence analysis of 16Se23S intergenic spacer. The minimal inhibitory concentrations
of antibiotics were determined by the agar dilution method.
Results: The nonsusceptibility rates of carbepenems and sulbactam were highest in A bauman-
nii, which also showed a trend toward increasing rate of carbapenems nonsusceptibility overby grants from Taipei Veterans General Hospital (V99C1-014) and National Science Council, Taiwan
Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2,
v.tw (T.-L. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Antibiotic nonsusceptibility trends in Acinetobacter baumannii complex 359the 11-year period of the study. AGS 13TU had the highest nonsusceptible rate to colistin,
comparably increasing trend of carbapenem nonsusceptiblity as that of A baumannii, and is
the only species with increasing sulbactam nonsusceptibility. AGS 3 had the lowest rate of non-
susceptibility to all four antimicrobial agents.
Conclusion: Although A baumannii had the highest nonsusceptibility rate to imipenem, mero-
penem, and sulbactam over the years, the higher rate of colistin nonsusceptibility and the
emergence of nonsusceptibility of carbapenems and sulbactam in AGS 13TU suggested that this
species might cause a great problem in the near future.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The nosocomial infection because of Acinetobacter bau-
mannii complex is associated with a high-mortality rate in
debilitated patients.1,2 These bacteria pose a great threat to
health care systems and infection control because they
develop antibiotic resistance by means of multiple mecha-
nisms.3 Carbapenems including imipenem and meropenem
are the antibiotics of last resort for the treatment of multi-
drug-resistant A baumannii complex.4 However, strains
resistant to carbapenems have been evolving worldwide,
which has limited the choice of treatment and mandated the
use of other therapeutic agents such as tigecycline, colistin,
or sulbactam.3,4
The genus Acinetobacter contains more than 32 species,
but A baumannii, Acinetobacter genomic species 3 (AGS 3),
and Acinetobacter genomic species 13TU (AGS 13TU) are the
three most clinically relevant pathogens. These three
species are phenotypically similar and cannot be differen-
tiated by commercially available identification methods.1
They are grouped into the so-called A baumannii complex
and sometimes their properties are studied and described
collectively,1,5 including their antibiotic susceptibilities.6
However, many studies have reported differences in epide-
miology, resistance patterns, and resistance mechanisms
among A baumannii, AGS 3, and AGS 13TU.7e10 A baumannii
isolates are often more resistant to different classes of
antimicrobials than are AGS 3 and AGS 13TU.7 Furthermore,
the carbapenemases harbored by A baumannii are different
from those harbored by AGS 3 and 13TU. For example, car-
bapenem-hydrolyzing class D beta-lactamases are often
identified in A baumannii,11e13 whereas metallo-beta-lac-
tamases are more frequently detected in AGS 3 or AGS
13TU.8,10 Hence, it is crucial to investigate the three species
separately. To date, it is unknown whether antimicrobial
resistance trends differ among the three Acinetobacter spp.
This study aimed to identify the trends in the development of
antibiotic nonsusceptibility by A baumannii, AGS 3, and AGS
13TU in a medical center in Taiwan. A better understanding
of the antimicrobial nonsusceptibility patterns of these
pathogens and trends may improve hospital management
and control of A baumannii complex infection.
Materials and methods
Bacterial isolates
This study was conducted at Taipei Veterans General
Hospital, a 2,900-bed tertiary care medical center inTaiwan. Nonduplicate blood isolates from bacteremic
patients were consecutively collected from year 1997 to
2007 if they were phenotypically identified as A baumannii
complex by the 32GN system (bioMe´rieux, Marcy l’Etoile,
France). The bacteria were stored at 70C in trypticase
cystine agar (Difco Laboratories, Le Pont de Claix, France)
supplemented with 15% glycerol before use.
Genomic species identification
Multiplex polymerase chain reaction described previously14
was used to identify A baumannii. The nonbaumannii Aci-
netobacter spp were identified by amplification and
sequence analysis of 16S23S intergenic spacer using
universal primers as previously described.15
Antimicrobial susceptibilities
The minimum inhibitory concentrations (MICs) of imipe-
nem, meropenem, sulbactam, and colistin were deter-
mined by agar dilution methods according to the Clinical
and Laboratory Standards Institute (CLSI) guidelines.16
Enterococcus faecalis ATCC 29212, Escherichia coli ATCC
25922, E coli ATCC 35218, and Pseudomonas aeruginosa
ATCC 27853 were used for quality control. For imipenem
and meropenem, a MIC of 4 mg/mL was considered to be
susceptible, and those with MIC >4 mg/mL to be non-
susceptible; whereas for colistin, a MIC of 2 mg/mL was
considered to be susceptible, and those with MIC >2 mg/mL
to be nonsusceptible.16 Because there were no breakpoints
existed for sulbactam in the CLSI guidelines, we adapted
that for ampicillin/sulbactam as interpretation reference.
A MIC for sulbactam of 4 mg/mL was considered to be
susceptible for sulbactam, and those with MIC >4 mg/mL to
be nonsusceptible. The nonsusceptibility rate was defined
as the number of nonsusceptible isolates divided by the
total number of isolates.
Statistical methods
Each of the MICs of the four antibiotics for the three Acine-
tobacter genospecies during the study period was recorded.
Geometricmeans of theMICs of a single antibiotic for a single
species within 1 year were calculated. Trends of geometric
means of MICs over time of each of the four antimicrobial
agents for a single genomic species were assessed by simple
linear regression analyses. A p < 0.05 denoted a significant
linear association between the mean MIC of a single antibi-
otic for a single species and time period.
Table 1 The number and percentage of isolates identified
as Acinetobacter baumannii complex from blood samples
over 11 yr
Year Acinetobacter spp Total of
isolatesA baumannii AGS 13TU AGS 3
1997 25 (37.31%) 32 (47.76%) 10 (14.93%) 67
1998 47 (54.65%) 31 (36.05%) 8 (9.30%) 86
1999 38 (47.50%) 31 (38.75%) 11 (13.75%) 80
2000 36 (41.86%) 44 (51.16%) 6 (6.98%) 86
2001 45 (33.83%) 69 (51.88%) 19 (14.29%) 133
2002 25 (32.47%) 41 (53.25%) 11 (14.29%) 77
2003 27 (43.55%) 25 (40.32%) 10 (16.13%) 62
2004 43 (38.74%) 61 (54.95%) 7 (6.31%) 111
2005 43 (43.43%) 42 (42.42%) 14 (14.14%) 99
2006 47 (41.59%) 43 (38.05%) 23 (20.35%) 113
2007 63 (50.40%) 48 (38.40%) 14 (11.20%) 125
AGS Z Acinetobacter genomic species.
360 C. Liang-Yu et al.To describe the relationship between the emergence of
nonsusceptible strains of each Acinetobacter species and
the time period, two-dimensional plots with trend lines were
used for descriptive analysis. The emergence of non-
susceptible strains as a function of time (year) was tested by
logistic regression analysis, using the emergence of non-
susceptible strains as a binary dependent variable (antimi-
crobial resistance vs. sensitivity), and time (continuous
variable) as a co-variable, and data were expressed as beta
and p values. Plus or minus values of beta denoted the
directions (increase or decrease) of the resistance, and
a p < 0.05 in this logistic regression model indicated
a significant increase or decrease of resistance rate year
after year during this 11-year period.
All statistical analyses were performed using SPSS soft-
ware (version 13.00, SPSS, Chicago, IL, USA).Table 2 Geometric mean of MICs of four antimicrobial agent
samples over 11 yr
Antibiotics Acinetobacter spp Geomet
1997 1998 1999 2000
Imipenem A baumannii 0.90 1.23 1.67 1.56
AGS 13TU 0.42 0.67 0.37 0.44
AGS 3 0.35 0.42 0.69 2.00
Meropenem A baumannii 1.25 1.16 1.47 1.78
AGS 13TU 0.68 0.84 0.49 0.85
AGS 3 0.66 0.50 1.37 2.24
Sulbactam A baumannii 8.22 7.54 8.45 9.51
AGS 13TU 2.00 1.96 1.79 1.88
AGS 3 2.30 1.68 3.31 1.78
Colistin A baumannii 1.18 1.06 1.18 0.96
AGS 13TU 2.43 1.71 2.67 1.94
AGS 3 1.62 1.30 1.37 1.59
* p Value < 0.05.
AGS Z Acinetobacter genomic species; MIC Z minimum inhibitory coResults
Isolates and species identification
A total of 1,039 isolates of A baumannii (439 isolates,
42.25%), AGS 13TU (467, 44.95%), and AGS 3 (133, 12.80%)
were collected during the study period. The percentage of
isolates identified as particular species and sorted by year
was listed in Table 1.
The MIC distribution
From year 1997 to 2007, the mean MICs of imipenem and
meropenem for A baumannii increased from 0.9 to
3.43 mg/L (p < 0.001) and 1.25 to 3.74 (p < 0.001),
respectively (Table 2). The mean MICs of imipenem, mer-
openem, and sulbactam for AGS 13TU increased from 0.42
to 0.93 (p Z 0.001), 0.68 to 1.43 (p Z 0.001), and 2.00 to
3.13 (p Z 0.003), respectively. The mean MICs of imipe-
nem, meropenem, and sulbactam remained stable for AGS
3. The mean MICs of colistin were unchanged for all three
species throughout the survey period.
Resistance rate and trends of resistance
A baumannii and AGS 13TU had higher nonsusceptibility
rate of imipenem and meropenem than AGS 3 (Fig.1 A, B).
A baumannii and AGS 13TU also had significant increase in
nonsusceptibility rates of imipenem and meropenem over
11 years (all p < 0.001), but AGS 3 did not. The non-
susceptibility rate of imipenem seemed to increase more
rapidly in A baumannii than AGS 13TU (beta, 0.275 and
0.207, respectively), whereas the emergence of non-
susceptibility for meropenem was faster in AGS 13TU than A
baumannii (beta, 0.327 and 0.298, respectively). Although
the nonsusceptibility rate of sulbactam in A baumannii wass in different Acinetobacter baumannii complex from blood
ric mean of MICs versus year p
2001 2002 2003 2004 2005 2006 2007
1.66 2.43 3.17 3.09 3.19 2.65 3.43 <0.001*
0.70 0.73 0.80 0.90 1.30 1.08 0.93 0.001*
0.50 0.47 0.38 0.34 0.67 0.49 0.32 0.532
1.69 2.11 3.52 2.89 3.19 3.16 3.74 <0.001*
1.14 0.64 1.18 1.31 1.67 1.60 1.43 0.001*
0.90 0.41 0.87 0.74 1.28 1.03 0.86 0.975
7.07 8.69 9.33 8.25 7.50 11.23 11.25 0.064
2.28 1.78 3.20 2.27 3.39 3.24 3.13 0.003*
2.68 1.88 1.87 1.81 2.32 2.06 1.81 0.396
1.11 0.90 0.90 0.86 1.17 1.06 1.10 0.532
1.79 2.58 2.23 1.52 1.87 1.62 1.86 0.156
1.39 1.00 1.15 1.00 1.35 1.31 1.72 0.725
ncentration.
Figure 1. Two-dimensional plots with trend lines of nonsusceptibility percentage to (A) imipenem, (B) meropenem, (C) sul-
bactam, and (D) colistin in each Acinetobacter spp versus time period (from 1997 to 2007, 11-year period).
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the only species with increasing nonsusceptibility rate of
sulbactam (p < 0.001). The nonsusceptibility rate of sul-
bactam in AGS 3 was the lowest among the three species
and did not change significantly over 11 years. AGS 13TU
had higher rate of nonsusceptibility to colistin than did A
baumannii and AGS3 (Fig. 1 D). The susceptibility of these
three species to colistin remained unchanged over 11 years.Discussion
A baumannii has long been considered as the most common
pathogen in the A baumannii complex.1 A study from
southern Taiwan showed that 75.9%, 23.0%, and 0.7% of 291
A baumannii complex isolates recovered from bacteremic
patients over a 5.5-year period were A baumannii, AGS 3,
and AGS 13TU, respectively.7 Unexpectedly, our study
demonstrated that the number of AGS 13TU isolates was
equal to, or even higher than that of A baumannii in some
years. The potential for bias was reduced by followingtrends over 11 years and consecutive collection of blood
samples. It is worth to study in the future that whether the
increase of AGS 13TU is caused by clonal spreading.
The carbapenem nonsusceptibility rate of A baumannii
has risen in recent years especially in countries of the Asia-
Pacific rim.3 Our study revealed that among species of the A
baumannii complex, A baumannii had the highest rate of
resistance to carbapenem and sulbactam. Although carba-
penem nonsusceptibility tended to increase, sulbactam
nonsusceptibility did not change significantly. However, the
changes of nonsusceptibility rates had more clinical impli-
cation than that of MICs did. Therefore, we examined the
antimicrobial nonsusceptibility rates of each Acinetobacter
spp during the 11-period (Fig. 1), and analyzed the trends
of antimicrobial nonsusceptibility among them.
The increase in antimicrobial nonsusceptibility rates
might be related to spreading of resistant determinants, or
a clonal outbreak within this hospital. Nosocomial infection
is common and there were reports of nosocomial outbreak of
carbapenemase-resistant A baumannii in the intensive care
units.17e19 Interhospital dissemination of imipenem-resistant
362 C. Liang-Yu et al.Acinetobacter spp with carbapenemase gene was also
reported by Kuo et al.12 recently in Taiwan. Inorganic
materials such as computer keyboards in the nursing station
might play a role as potential reservoirs of these resistant
pathogens.20 Plasmid transfer of carbapenemase gene had
also been reported.21
The most worrisome finding was the emergence of non-
susceptibility in AGS 13TU. The nonsusceptibility of AGS
13TU has gradually gained attention, but the power of
these studies was hampered by small number of isolates or
diversity of samples.8,9 Our study revealed that non-
susceptibility to carbapenems (imipenem and meropenem)
in AGS 13TU was accelerating, suggesting that AGS 13TU
may be developing similar carbapenem nonsusceptibility
rate equal to that of A baumannii in the near future. In this
study, sulbactam nonsusceptibility rate was higher in A
baumannii than in AGS 13TU, but it has been increasing in
AGS 13TU at a rate approaching that of A baumannii during
the years. The finding of a higher rate of nonsusceptibility
to colistin in AGS 13TU than A baumannii is consistent with
previous findings.9,22
In contrast to the evolving of nonsusceptibility rate in A
baumannii and AGS 13TU, AGS 3 was constantly more
susceptible to carbapenems and sulbactam in our study.
The nonsusceptibility to these antimicrobials or colistin did
not increase over years, which may imply a difference
among AGS3, A baumannii, and AGS 13TU in ability to
acquire nonsusceptibility.7e10
Although we did not evaluate the patients outcome, the
increased geometric mean MIC and MIC90 through
1997e2007 would probably related to higher rate of treat-
ment failure and worse prognosis in the clinical situation.
Higher mortality rate related to inadequate treatment on A
baumannii complex infection had been reported.23
We did not include tigecycline in this study because
currently there is no tigecycline breakpoint for Acineto-
bacter spp according to CLSI guidelines16 and the use of
tigecycline in the treatment of bacteremic patients is
generally not recommended because of low-plasma
concentration.
In conclusion, our study of a large collection of isolates
over a prolonged period revealed a difference in antimi-
crobial resistance and emergence of resistance among A
baumannii, AGS 13TU, and AGS 3. A baumannii had the
highest rate of nonsusceptibility to carbapenems and sul-
bactam in recent years, but the higher resistance rate to
colistin and rapid emergence of carbapenems and sulbac-
tam nonsusceptibility in AGS 13TU indicated that thera-
peutic options for the treatment of patients with AGS 13TU
bacteremia might become limited in the near future.Acknowledgment
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